New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Belite Bio, Inc

Contributing Author

Recent Articles by Belite Bio, Inc

Sep-12	Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease BLTE GlobeNewswire
Sep-08	Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors BLTE GlobeNewswire
Aug-27	Belite Bio to Participate in Three Upcoming Investor Conferences BLTE GlobeNewswire
Aug-11	Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update BLTE GlobeNewswire
Aug-07	Belite Bio Announces Registered Direct Offering of $15 Million BLTE GlobeNewswire
Aug-06	Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference BLTE GlobeNewswire
Aug-04	Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results BLTE GlobeNewswire
Jul-23	Belite Bio to Participate in the BTIG Virtual Biotechnology Conference BLTE GlobeNewswire
Jul-02	Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy BLTE GlobeNewswire
May-21	Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease BLTE GlobeNewswire
May-13	Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update BLTE GlobeNewswire
May-12	Belite Bio to Participate in Four Upcoming Investor Conferences BLTE GlobeNewswire
May-07	Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results BLTE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.